Study on MCLA-129 Antibody Treatment for Advanced Lung and Other Solid Tumors

Sponsor: Merus N.V.

Sponsor score: 40
Inactive

ClinicalTrials ID:NCT04868877

Provider View

This clinical trial is testing a new antibody treatment, MCLA-129, for patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors. The study aims to find the best dose and evaluate the treatment's effectiveness, both alone and in combination with other therapies.

Patient Parameters

Program Overview

This study is exploring a new treatment called MCLA-129, which is an antibody designed to target specific proteins involved in cancer growth. The trial is open to patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors, including head and neck, stomach, and esophageal cancers. The study will determine the safest and most effective dose of MCLA-129, either on its own or combined with other treatments, for patients who have not responded to previous therapies or are newly diagnosed.

Eligibility Criteria

Exclusion Criteria

  • Have untreated or symptomatic cancer that has spread to the brain or requires ongoing treatment with steroids or other therapies.
  • Have cancer that has spread to the membranes surrounding the brain and spinal cord.
  • Are participating in another clinical trial or have taken an experimental drug within the last 4 weeks.
  • Have received cancer treatment or immunotherapy within the last 4 weeks or 5 half-lives of the drug, whichever is shorter.
  • Have had major surgery or radiation therapy within the last 3 weeks.
  • Have significant side effects from previous cancer treatments, except for hair loss or stable mild nerve damage or thyroid issues.
  • Have had severe allergic reactions to proteins or ingredients in the study drug.
  • Have significant heart disease.
  • Have a history of lung inflammation or pneumonitis.
  • Have another type of cancer, unless it was treated and is not expected to affect the study.
  • Have serious illnesses or medical conditions, such as uncontrolled infections or significant lung, metabolic, or mental health disorders.
  • Have active Hepatitis B without treatment.
  • Test positive for Hepatitis C.
  • Have a known history of HIV, unless the viral load is undetectable.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.